Journal article icon

Journal article

Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study

Abstract:
Abstract Purpose Beta blockers (BB) have been associated with improved, worsened, or unchanged breast cancer outcomes in previous studies. This study examines the association between the post-diagnostic use of BBs and death from breast cancer in a large, representative sample of New Zealand (NZ) women with breast cancer. Methods Women diagnosed with a first primary breast cancer between 2007 and 2016 were identified from four population-based regional NZ breast cancer registries and linked to national pharmaceutical data, hospital discharges, and death records. The median follow-up time was 4.51 years. Cox proportional hazard models were used to estimate the hazard of breast cancer-specific death (BCD) associated with any post-diagnostic BB use. Results Of the 14,976 women included in analyses, 21% used a BB after diagnosis. BB use (vs non-use) was associated with a small and nonstatistically significant increased risk of BCD (adjusted hazard ratio: 1.11; 95% CI 0.95–1.29). A statistically significant increased risk confined to short-term use (0–3 months) was seen (HR = 1.40; 1.14–1.73), and this risk steadily decreased with increasing duration of use and became a statistically significant protective effect at 3 + years of use (HR = 0.55; 0.34–0.88). Conclusion Our findings suggest that any increased risk associated with BB use may be driven by risk in the initial few months of use. Long-term BB use may be associated with a reduction in BCD.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1007/s10549-022-06528-0

Authors

More by this author
Role:
Author
ORCID:
0000-0002-8994-2760
More by this author
Institution:
University of Oxford
Role:
Author
More by this author
Role:
Author
ORCID:
0000-0001-5730-4791
More by this author
Role:
Author
ORCID:
0000-0002-5709-367X
More by this author
Role:
Author
ORCID:
0000-0002-7230-587X


More from this funder
Funder identifier:
10.13039/501100001511
Grant:
1217004
More from this funder
Funder identifier:
10.13039/501100001537


Publisher:
Springer
Journal:
Breast Cancer Research and Treatment More from this journal
Volume:
193
Issue:
1
Pages:
225-235
Publication date:
2022-03-14
DOI:
EISSN:
1573-7217
ISSN:
0167-6806


Language:
English
Keywords:
Pubs id:
1247021
Local pid:
pubs:1247021
Source identifiers:
W4220779215
Deposit date:
2026-04-10
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP